Skip to main content
SpringerLink
Log in

Liver Metastases of Neuroendocrine Tumors and CCC

  • Chapter
  • First Online:
Locoregional Tumor Therapy

  • 482 Accesses

Abstract

With an increasing annual incidence of about 5/100,000, neuroendocrine tumors (NET) are relatively rare tumors [1]. They originate from different types of hormone-producing neuroendocrine cells located not only in endocrine glands like the thyroid but in almost every tissue. Even when NET can arise in almost every part of the body, the lung (about 30 % of all NETs) and the gastroenteropancreatic system – so-called GEP (small intestine 17 %, colorectal 12 %, pancreatic 7 %) – are the most common locations [1]. Especially, the GEP-NETs are often diagnosed at an already advanced tumor stage (UICC IV) exhibiting liver metastases. There are two different groups of GEP-NETs – hormonally inactive (70 %) and hormonally active (30 %) tumors that produce different types of hormones including insulin (insulinoma), gastrin (gastrinoma), or serotonin. The patient’s clinical symptoms depend on the type of hormone produced: e.g., insulin, hypoglycemia; gastrin, peptic ulcers; and serotonin, flush.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 24.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey J-N, Rashid A, Evans DB. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72.

    Article  PubMed  Google Scholar 

  2. Mitry E, Baudin E, Ducreux M, Sabourin JC, Rufié P, Aparicio T, Lasser P, Elias D, Duvillard P, Schlumberger M, Rougier P. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer. 1999;81:1351–5.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  3. Moertel CG, Kvols LK, O’Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer. 1991;68:227–32.

    Article  CAS  PubMed  Google Scholar 

  4. Eriksson B, Annibale B, Bajetta E, Mitry E, Pavel M, Platania M, Salazar R, Plöckinger U. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: chemotherapy in patients with neuroendocrine tumors. Neuroendocrinology. 2009;90:214–9.

    Article  CAS  PubMed  Google Scholar 

  5. Bajetta E, Catena L, Procopio G, de Dosso S, Bichisao E, Ferrari L, Martinetti A, Platania M, Verzoni E, Formisano B, Bajetta R. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol. 2007;59:637–42.

    Article  CAS  PubMed  Google Scholar 

  6. Rinke A, Müller H-H, Schade-Brittinger C, Klose K-J, Barth P, Wied M, Mayer C, Aminossadati B, Pape U-F, Bläker M, Harder J, Arnold C, Gress T, Arnold R. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27:4656–63.

    Article  CAS  PubMed  Google Scholar 

  7. Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen D-T, Helm J, Kvols L. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer. 2011;117:268–75.

    Article  CAS  PubMed  Google Scholar 

  8. Raymond E, Dahan L, Raoul J-L, Bang Y-J, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen J-S, Hörsch D, Hammel P, Wiedenmann B, van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:501–13.

    Article  CAS  PubMed  Google Scholar 

  9. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EGE, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Öberg K. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514–23.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, Feelders RA, van Aken MO, Krenning EP. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124–30.

    Article  CAS  PubMed  Google Scholar 

  11. Christante D, Pommier S, Givi B, Pommier R. Hepatic artery chemoinfusion with chemoembolization for neuroendocrine cancer with progressive hepatic metastases despite octreotide therapy. Surgery. 2008;144:885–93; discussion 893–4.

    Article  PubMed  Google Scholar 

  12. Fiorentini G, Rossi S, Bonechi F, Vaira M, de Simone M, Dentico P, Bernardeschi P, Cantore M, Guadagni S. Intra-arterial hepatic chemoembolization in liver metastases from neuroendocrine tumors: a phase II study. J Chemother. 2004;16:293–7.

    Article  CAS  PubMed  Google Scholar 

  13. Gupta S, Johnson MM, Murthy R, Ahrar K, Wallace MJ, Madoff DC, McRae SE, Hicks ME, Rao S, Vauthey J-N, Ajani JA, Yao JC. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer. 2005;104:1590–602.

    Article  PubMed  Google Scholar 

  14. Ho AS, Picus J, Darcy MD, Tan B, Gould JE, Pilgram TK, Brown DB. Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors. AJR Am J Roentgenol. 2007;188:1201–7.

    Article  PubMed  Google Scholar 

  15. Kress O, Wagner H-J, Wied M, Klose KJ, Arnold R, Alfke H. Transarterial chemoembolization of advanced liver metastases of neuroendocrine tumors–a retrospective single-center analysis. Digestion. 2003;68:94–101.

    Article  CAS  PubMed  Google Scholar 

  16. Osborne DA, Zervos EE, Strosberg J, Strosberg J, Boe BA, Malafa M, Rosemurgy AS, Yeatman TJ, Carey L, Duhaine L, Kvols LK. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol. 2006;13:572–81.

    Article  PubMed  Google Scholar 

  17. Touzios JG, Kiely JM, Pitt SC, Rilling WS, Quebbeman EJ, Wilson SD, Pitt HA. Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg. 2005;241:776–83; discussion 783–5.

    Article  PubMed Central  PubMed  Google Scholar 

  18. Vogl TJ, Naguib NNN, Zangos S, Eichler K, Hedayati A, Nour-Eldin N-EA. Liver metastases of neuroendocrine carcinomas: interventional treatment via transarterial embolization, chemoembolization and thermal ablation. Eur J Radiol. 2009;72:517–28.

    Article  PubMed  Google Scholar 

  19. Kratochwil C, Giesel FL, López-Benítez R, Schimpfky N, Kunze K, Eisenhut M, Kauczor H-U, Haberkorn U. Intraindividual comparison of selective arterial versus venous 68Ga-DOTATOC PET/CT in patients with gastroenteropancreatic neuroendocrine tumors. Clin Cancer Res. 2010;16:2899–905.

    Article  CAS  PubMed  Google Scholar 

  20. McStay MKG, Maudgil D, Williams M, Tibballs JM, Watkinson AF, Caplin ME, Buscombe JR. Large-volume liver metastases from neuroendocrine tumors: hepatic intraarterial 90Y-DOTA-lanreotide as effective palliative therapy. Radiology. 2005;237:718–26.

    Article  PubMed  Google Scholar 

  21. Kennedy AS, Dezarn WA, McNeillie P, Coldwell D, Nutting C, Carter D, Murthy R, Rose S, Warner RRP, Liu D, Palmedo H, Overton C, Jones B, Salem R. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol. 2008;31:271–9.

    Article  PubMed  Google Scholar 

  22. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin. 1998;48:6–29.

    Article  CAS  PubMed  Google Scholar 

  23. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273–81.

    Article  CAS  PubMed  Google Scholar 

  24. Ortner MEJ, Caca K, Berr F, Liebetruth J, Mansmann U, Huster D, Voderholzer W, Schachschal G, Mössner J, Lochs H. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology. 2003;125:1355–63.

    Article  PubMed  Google Scholar 

  25. Zoepf T, Jakobs R, Arnold JC, Apel D, Riemann JF. Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. Am J Gastroenterol. 2005;100:2426–30.

    Article  CAS  PubMed  Google Scholar 

  26. Gusani NJ, Balaa FK, Steel JL, Geller DA, Marsh JW, Zajko AB, Carr BI, Gamblin TC. Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): a single-institution experience. J Gastrointest Surg. 2008;12:129–37.

    Article  PubMed  Google Scholar 

  27. Kirchhoff T, Zender L, Merkesdal S, Frericks B, Malek N, Bleck J, Kubicka S, Baus S, Chavan A, Manns M-P, Galanski M. Initial experience from a combination of systemic and regional chemotherapy in the treatment of patients with nonresectable cholangiocellular carcinoma in the liver. World J Gastroenterol. 2005;11:1091–5.

    PubMed  Google Scholar 

  28. Cantore M, Mambrini A, Fiorentini G, Rabbi C, Zamagni D, Caudana R, Pennucci C, Sanguinetti F, Lombardi M, Nicoli N. Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors. Cancer. 2005;103:1402–7.

    Article  CAS  PubMed  Google Scholar 

  29. Burger I, Hong K, Schulick R, Georgiades C, Thuluvath P, Choti M, Kamel I, Geschwind J-FH. Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution. J Vasc Interv Radiol. 2005;16:353–61.

    Article  PubMed  Google Scholar 

  30. Vogl TJ, Schwarz W, Eichler K, Hochmuth K, Hammerstingl R, Jacob U, Scheller A, Zangos S, Heller M. Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinomas and liver metastases of pancreatic cancer: a clinical study on maximum tolerable dose and treatment efficacy. J Cancer Res Clin Oncol. 2006;132:745–55.

    Article  CAS  PubMed  Google Scholar 

  31. Mambrini A, Guglielmi A, Pacetti P, Iacono C, Torri T, Auci A, Nicoli N, Orlandi M, Guadagni S, Fiorentini G, Cantore M. Capecitabine plus hepatic intra-arterial epirubicin and cisplatin in unresectable biliary cancer: a phase II study. Anticancer Res. 2007;27:3009–13.

    CAS  PubMed  Google Scholar 

  32. Herber S, Otto G, Schneider J, Manzl N, Kummer I, Kanzler S, Schuchmann A, Thies J, Düber C, Pitton M. Transarterial chemoembolization (TACE) for inoperable intrahepatic cholangiocarcinoma. Cardiovasc Intervent Radiol. 2007;30:1156–65.

    Article  CAS  PubMed  Google Scholar 

  33. Kim JH, Yoon H-K, Sung K-B, Ko G-Y, Gwon DI, Shin JH, Song H-Y. Transcatheter arterial chemoembolization or chemoinfusion for unresectable intrahepatic cholangiocarcinoma: clinical efficacy and factors influencing outcomes. Cancer. 2008;113:1614–22.

    Article  PubMed  Google Scholar 

  34. Aliberti C, Benea G, Tilli M, Fiorentini G. Chemoembolization (TACE) of unresectable intrahepatic cholangiocarcinoma with slow-release doxorubicin-eluting beads: preliminary results. Cardiovasc Intervent Radiol. 2008;31:883–8.

    Article  PubMed  Google Scholar 

  35. Poggi G, Amatu A, Montagna B, Quaretti P, Minoia C, Sottani C, Villani L, Tagliaferri B, Sottotetti F, Rossi O, Pozzi E, Zappoli F, Riccardi A, Bernardo G. OEM-TACE: a new therapeutic approach in unresectable intrahepatic cholangiocarcinoma. Cardiovasc Intervent Radiol. 2009;32:1187–92.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine I, Ulm University, Ulm, Germany

    Thomas Ettrich & Thomas Seufferlein

Authors
  1. Thomas Ettrich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas Seufferlein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas Ettrich .

Editor information

Editors and Affiliations

  1. Department of Oncology, University Hospital Gasthuisberg Leuven Cancer Institute, Leuven, Belgium

    Eric Van Cutsem

  2. Department of Diagostic Radiology, Johann Wolfgang Goethe University, Frankfurt am Main, Germany

    Thomas J. Vogl

  3. Department of Radiology, European Institute of Oncology, Milano, Italy

    Franco Orsi

  4. Department of Medical Oncology, IRCCS Ospedale San Martino IST, Genova, Italy

    Alberto Sobrero

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Ettrich, T., Seufferlein, T. (2015). Liver Metastases of Neuroendocrine Tumors and CCC. In: Van Cutsem, E., Vogl, T., Orsi, F., Sobrero, A. (eds) Locoregional Tumor Therapy. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-36572-0_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-36572-0_6

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-36571-3

  • Online ISBN: 978-3-642-36572-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation